Further preclinical assessment of compound EL102 in the treatment of prostate cancer.

e16053 Background: EL102 was selected from a screen of NCI-60 panel assessing growth inhibition potential. Previously, we presented findings on this toluidinesulfonamide(TS) as a candidate for pros...